BIOXYTRAN, INC (BIXT) Bioxytran, Inc. is a pharmaceutical firm operating in the clinical development phase, dedicated to creating, producing, and marketing medicinal treatments for oxygen deficiency (hypoxia) in people. Its primary drug under development, BXT-25, is a small, oxygen-transporting molecule crafted from bovine hemoglobin, stabilized by a co-polymer. This compound is intended for tackling oxygen deprivation in the brain caused by strokes, as well as addressing wound hypoxia to avert tissue death and encourage recovery. Additionally, Bioxytran is advancing ProLectin-Rx, a pectin-derived polysaccharide. This substance functions by attaching to and inhibiting galectin-1, a specific galectin, to treat mild to moderate instances of Covid-19. Established in 2008, the company maintains its main office in Newton, Massachusetts.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Bioxytran, Inc. OTC:BIXT Healthcare · Biotechnology
Mkt Cap $2.83M
EV -
SI <0.1%
Net Cash/Sh -
AH After hours +0.00% $0.0247
Prev close $0.0222 +11.26%Close $0.0247 0.00% Now $0.0247 VOL 76K $ Vol $2K RVOL 0.89x
Mkt Cap $2.83M
EV -
VOL 76K sh
$ Vol $2K
RVOL 0.89×
SI <0.1%
Net Cash/Sh -
Press Release
Bioxytran Turns Science into Everyday Wellness with Launch of Its First Two Nutraceutical Products
Bioxytran launched its first two nutraceutical products: A-SUQAR for post-meal blood sugar support and V-LO for immune support, marking a move into consumer wellness. The products are sold directly via the company's Shopify store and are built on its carbohydrate-chemistry expertise; no FDA evaluation and no revenue figures were disclosed.
• 1d ago AI analysis › Press Release
Bioxytran Secures Attested Free Sale Certification for A-SUQAR®, Opening the Path to the UAE and Gulf Markets
Bioxytran received a government-issued, attested Free Sale Certificate for A-SUQAR, its pre-meal chewable supplement designed to blunt post-meal blood sugar spikes. The certificate is a key regulatory document for product registration and market entry in the UAE and the wider GCC region, where roughly 7.5 million adults across the UAE, Saudi Arabia and Kuwait live with diabetes.
• 13d ago AI analysis › Press Release
Bioxytran Completes Production of Two Dietary Supplements: V-LO® for Immune Health and A-SUQAR® for Healthy Blood Sugar
Bioxytran has completed production of finished inventory for its first two consumer dietary supplements, V-LO® for immune support and A-SUQAR® for healthy blood sugar. The company is finalizing go-to-market plans across e-commerce, retail, and distribution channels, with launch timing to be announced later; A-SUQAR® is already covered by a February 2026 distribution agreement with Khoury Medical LTD for the Middle East.
• 29d ago AI analysis › Press Release
Bioxytran Reports Encouraging Clinical Observations in First Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Patient Treated with PLICID, a Novel Galectin Antagonist Designed with Artificial Intelligence
Bioxytran reported positive clinical observations from the first CIDP patient treated with its investigational drug PLICID, noting improvements in finger function and walking ability with no adverse events. PLICID is a galectin antagonist designed using the company's proprietary ASI-driven platform, developed with researchers at the University of Minnesota.
• 3mo ago AI analysis › Press Release
Bioxytran Leverages Artificial Super Intelligence (ASI) to Design Broad-Spectrum Antiviral and Anti-Cancer Metastasis Drugs
Bioxytran entered a second Sponsored Research Agreement with the University of Minnesota’s Department of Chemistry to advance its ASI-powered carbohydrate drug design platform. The release cited Phase 2 data for lead asset ProLectin-M, reporting that 100% of patients achieved viral loads below the assay’s limit of detection by day seven, compared to 20% in the placebo arm by day five.
• 3mo ago AI analysis › Press Release
Bioxytran Announces Publication of Corporate Research Report by Globe Small Cap Research
Bioxytran announced the publication of a sponsored research report by Globe Small Cap Research that reviews its therapeutic pipeline and commercial strategies. The report highlights positive Phase 2 results for ProLectin-M, noting treated patients achieved undetectable viral loads by Day 7, and discusses a proposed 408-patient registrational trial.
• 3mo ago AI analysis › Press Release
Bioxytran Highlights New Book on Real-Time Monitoring Tissue Oxygenation Relevant to Oxygen Carrier BXT-25
Bioxytran highlighted the publication of a new scientific book by Dr. Avraham Mayevsky titled 'Physiological Mapping of the Cerebral Cortex in Neuropathology.' The book introduces 'Physiological Mapping,' a methodology for real-time monitoring of tissue metabolism and oxygenation, which Bioxytran believes may complement the future evaluation of its investigational oxygen therapeutic BXT-25. The release notes that Dr.
• 5mo ago AI analysis ›